Methicillin-Resistant Staphylococcus Aureus | Pharmacor | G7 | 2014

Methicillin-resistant Staphylococcus aureus (MRSA) is an important causative pathogen of a range of hospital-treated infections. The steadily increasing severity of infections caused by MRSA that require hospital treatment and the decreasing susceptibility of this pathogen to current antibiotics continue to drive the need for novel therapies. The success of two agents—linezolid (Pfizer’s Zyvox/Zyvoxid) and daptomycin (Cubist/Novartis/Merck’s Cubicin)—has demonstrated the commercial potential that can be achieved in this market and has contributed to continued interest in drug development for novel antibiotics active against MRSA. With up to eight new emerging therapies set to launch by 2022, the competition within the hospital-treated MRSA (HT-MRSA) market will intensify as a growing number of therapies compete for limited patient share. Therefore, new emerging therapies will find uptake in segments of the HT-MRSA market with high unmet need, helping sustain the market even as key branded agents lose patent protection.

Login to access report

launch Related Market Assessment Reports